StockData
AngioDynamics Inc logo

AngioDynamics Inc (ANGO) stock

ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 12/306% below fair value
$11.98−0.44 (-3.50%)

Close on Nov 12, 2026Market cap $504.02MP/E –Yield –

Earnings

AngioDynamics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 5, 2027
Q2 FY2027 · estimated, before the open
Revenue, Q1 FY2027
$80.90M
+6.9% on a year earlier
Adjusted loss per share, Q1 FY2027
-$0.04
-$0.10 a year earlier
Latest guidance
Reaffirmed
Oct 8, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of AngioDynamics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2027ended Nov 30, 2026Jan 5, 2027Expected–––––
Q1 FY2027ended Aug 31, 2026Oct 8, 2026before the open$80.90M+6.9%-$0.17-$0.04Release
Q4 FY2026ended May 31, 2026Jul 14, 2026before the open$86.60M+8.0%-$0.27-$0.07Release
Q3 FY2026ended Feb 28, 2026Apr 2, 2026before the open$78.40M+8.9%-$0.19-$0.07Release
Q2 FY2026ended Nov 30, 2025Jan 6, 2026before the open$79.40M+8.8%-$0.15$0.00Release
Q1 FY2026ended Aug 31, 2025Oct 2, 2025before the open$75.70M+12.1%-$0.26-$0.10Release
Q4 FY2025ended May 31, 2025Jul 15, 2025before the open$80.20M+6.7%-$0.15-$0.03Release
Q3 FY2025ended Feb 28, 2025Apr 2, 2025before the open$72.00M–-$0.11-$0.08Release
Q2 FY2025ended Nov 30, 2024Jan 8, 2025before the open$73.00M-7.7%-$0.26-$0.04Release
Q1 FY2025ended Aug 31, 2024Oct 3, 2024before the open$67.50M-14.2%$0.31$0.11Release
Q4 FY2024ended May 31, 2024Jul 16, 2024before the open$75.18M-17.5%-$4.67-$0.16Release
Q3 FY2024ended Feb 29, 2024Apr 4, 2024before the open––-$4.73-$0.16Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

AngioDynamics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net SalesFY2027$336.00M – $341.00M$336.00M – $341.00MReaffirmedOct 8, 2026
Gross MarginFY202754% – 55%54% – 55%ReaffirmedOct 8, 2026
Adjusted EBITDAnon-GAAPFY2027$13.00M – $16.00M$13.00M – $16.00MReaffirmedOct 8, 2026
Adjusted EPSnon-GAAPFY2027-$0.29 – -$0.24-$0.29 – -$0.24ReaffirmedOct 8, 2026
Med Tech Net Sales GrowthFY2027+12% – +15%+12% – +15%ReaffirmedOct 8, 2026

Guidance vs results

The last range AngioDynamics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2026Adjusted EPS-$0.30 – -$0.23-$0.24Σ4QWithin range
FY2026Revenue$313.50M – $315.50M$320.10MΣ4QAbove range
FY2025Adjusted loss per share-$0.34 – -$0.31-$0.04Σ4QAbove range
FY2025Revenue$285.00M – $288.00M$292.70MΣ4QAbove range

Guidance history

Every forecast AngioDynamics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 8, 2026Adjusted EBITDAFY2027$13.00M – $16.00MReaffirmed
Oct 8, 2026Adjusted EPSFY2027-$0.29 – -$0.24Reaffirmed
Oct 8, 2026Gross MarginFY202754% – 55%Reaffirmed
Oct 8, 2026Med Tech Net Sales GrowthFY2027+12% – +15%Reaffirmed
Oct 8, 2026Net SalesFY2027$336.00M – $341.00MReaffirmed
Jul 14, 2026Adjusted EBITDAFY2027$13.00M – $16.00MNew
Jul 14, 2026Adjusted EPSFY2027-$0.29 – -$0.24New
Jul 14, 2026Gross MarginFY202754% – 55%New
Jul 14, 2026Med Tech Net Sales GrowthFY2027+12% – +15%New
Jul 14, 2026Net SalesFY2027$336.00M – $341.00MNew
Apr 2, 2026Adjusted EBITDAFY2026$10.00M – $12.00MRaised
Apr 2, 2026Adjusted EPSFY2026-$0.30 – -$0.23Raised
Apr 2, 2026Gross MarginFY202653.5% – 55.5%Reaffirmed
Apr 2, 2026Med Device Net Sales GrowthFY2026+1%Lowered
Apr 2, 2026impact from tariffsFY2026$4.00M – $6.00MNew
Apr 2, 2026Med Tech Net Sales GrowthFY2026+15% – +17%Raised
Apr 2, 2026Net SalesFY2026$313.50M – $315.50MRaised
Oct 2, 2025Adjusted EBITDAFY2026$6.00M – $10.00MNew
Oct 2, 2025Adjusted EPSFY2026-$0.33 – -$0.23New
Oct 2, 2025Gross MarginFY202653.5% – 55.5%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AngioDynamics filed with the SEC as exhibits to Form 8-K or 6-K

  1. AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
    Results
  2. First Quarter FY 2027Earnings Results October 8, 2026
    Results
  3. AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
    Results
  4. Fourth Quarter and Full Year 2026Earnings Results July 14, 2026
    Results
  5. AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued
    Results
  6. Third Quarter FY 2026Earnings Results April 2, 2026
    Results
  7. J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President
    Update
  8. AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
    Results
  9. Second Quarter FY 2026Earnings Results January 6, 2026
    Results
  10. AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
    Results
  11. First Quarter FY 2026Earnings Results October 2, 2025
    Results
  12. AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth
    Results
  13. AngioDynamics Fourth Quarter and Full Year Earnings Presentation July
    Results
  14. INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative
    Update
  15. AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
    Results

See a number that looks wrong?